Moleculin Biotech (MBRX) Accumulated Expenses (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Accumulated Expenses of $1.8 million for Q4 2025, little changed year-over-year from $1.8 million in Q4 2024, and down 48.93% quarter-over-quarter from $3.6 million in Q3 2025.
Moleculin Biotech (MBRX) Accumulated Expenses (2016 - 2026) Analysis & Trends
Moleculin Biotech's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $1.8 million for Q4 2025.
- In Q4 2025, Accumulated Expenses changed 0.22% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $1.8 million (changed 0.22% YoY), while the FY2025 annual figure was $1.8 million, changed 0.22% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $1.8 million, down from $3.6 million in the prior quarter.
- The five-year high for Accumulated Expenses was $4.3 million in Q4 2023, with the low at $106000.0 in Q2 2021.
- The 5-year median for Accumulated Expenses is $1.9 million (2023), against an average of $2.0 million.
- The sharpest annual moves came in 2021 and 2023: Accumulated Expenses sank 94.18% in 2021, then surged 1639.57% in 2023.
- Moleculin Biotech's Accumulated Expenses stood at $2.3 million in 2021, then tumbled by 66.87% to $748000.0 in 2022, then surged by 477.14% to $4.3 million in 2023, then slumped by 57.91% to $1.8 million in 2024, then climbed by 0.22% to $1.8 million in 2025.
- Business Quant data shows MBRX's Accumulated Expenses at $1.8 million in Q4 2025, $3.6 million in Q3 2025, and $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.98 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 4.19 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | 3.04 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | 2.42 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 748,000.00 |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 139,000.00 |
| Mar 31, 2022 | 869,000.00 |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 2.27 Mn |
| Jun 30, 2021 | 106,000.00 |